Cipla Combo Malaria Drug Accepted By WHO For Asia Aid Group Buys
This article was originally published in PharmAsia News
Cipla's malaria drug has been cleared by the World Health Organization to be among treatments available in bulk for aid agencies to buy for treating the poor.
You may also be interested in...
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
Investors in surgical robotics company Auris say Johnson & Johnson failed to support the company per their merger agreement.